 - Histologically or cytologically confirmed diagnosis of stage IIIB and is not a candidate for definitive multimodality therapy or stage IV NSCLC demonstrated ALK-positive or an advanced tumor, other than NSCLC, that carries an ALK genetic alteration mutation, translocation or amplification andor ALK overexpression that has progressed despite standard therapy, or for which no effective standard therapy exists. 